118 related articles for article (PubMed ID: 38889606)
1. Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidin-7(8H)-one derivatives as potent USP1 inhibitors.
Li H; Liu BJ; Xu J; Song SS; Ba R; Zhang J; Huan XJ; Wang D; Miao ZH; Liu T; He JX; Xiong B
Eur J Med Chem; 2024 Jun; 275():116568. PubMed ID: 38889606
[TBL] [Abstract][Full Text] [Related]
2. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationship studies of N-benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer.
Dexheimer TS; Rosenthal AS; Luci DK; Liang Q; Villamil MA; Chen J; Sun H; Kerns EH; Simeonov A; Jadhav A; Zhuang Z; Maloney DJ
J Med Chem; 2014 Oct; 57(19):8099-110. PubMed ID: 25229643
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship.
Chen M; Huang H; Wu K; Liu Y; Jiang L; Li Y; Tang G; Peng J; Cao X
Drug Dev Res; 2022 Feb; 83(1):55-63. PubMed ID: 34151456
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
Gao CZ; Dong W; Cui ZW; Yuan Q; Hu XM; Wu QM; Han X; Xu Y; Min ZL
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):150-162. PubMed ID: 30427217
[TBL] [Abstract][Full Text] [Related]
8. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
[TBL] [Abstract][Full Text] [Related]
9. ML323 suppresses the progression of ovarian cancer
Song B; Jiang Y; Jiang Y; Lin Y; Liu J
Front Genet; 2022; 13():917481. PubMed ID: 35923700
[No Abstract] [Full Text] [Related]
10. New Quinoxaline-Based Derivatives as PARP-1 Inhibitors: Design, Synthesis, Antiproliferative, and Computational Studies.
Syam YM; Anwar MM; Abd El-Karim SS; Elokely KM; Abdelwahed SH
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956876
[TBL] [Abstract][Full Text] [Related]
11. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
13. Discovery of pyrido[3,2-d]pyrimidin-6(5H)-one derivatives as checkpoint kinase 1 (CHK1) inhibitors with potent antitumor efficacy.
Hu S; Jiang C; Jin Q
Eur J Med Chem; 2024 Apr; 269():116351. PubMed ID: 38547734
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation, and molecular modeling studies of new benzoxazole derivatives as PARP-2 inhibitors targeting breast cancer.
El-Ghobashy NM; El-Sayed SM; Shehata IA; El-Ashmawy MB
Sci Rep; 2022 Sep; 12(1):16246. PubMed ID: 36171229
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Ubiquitin Specific Protease 1 Sensitizes Colorectal Cancer Cells to DNA-Damaging Chemotherapeutics.
Xu X; Li S; Cui X; Han K; Wang J; Hou X; Cui L; He S; Xiao J; Yang Y
Front Oncol; 2019; 9():1406. PubMed ID: 31921663
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Bioevaluation of Pyrido[2,3-
Liu M; Zhou G; Su W; Gu Y; Gao M; Wang K; Huo R; Li Y; Zhou Z; Chen K; Zheng M; Zhang S; Xu T
ACS Med Chem Lett; 2023 Feb; 14(2):183-190. PubMed ID: 36793426
[TBL] [Abstract][Full Text] [Related]
17. 8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors.
Sakamoto T; Koga Y; Hikota M; Matsuki K; Mochida H; Kikkawa K; Fujishige K; Kotera J; Omori K; Morimoto H; Yamada K
Bioorg Med Chem Lett; 2015 Apr; 25(7):1431-5. PubMed ID: 25754491
[TBL] [Abstract][Full Text] [Related]
18. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability.
Gurkan-Alp AS; Alp M; Karabay AZ; Koc A; Buyukbingol E
Anticancer Agents Med Chem; 2020; 20(14):1728-1738. PubMed ID: 32357823
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
